Počet záznamů: 1
Cyclin-dependent kinase inhibitors as anticancer drugs
- 1.
SYSNO ASEP 0359286 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Cyclin-dependent kinase inhibitors as anticancer drugs Tvůrce(i) Kryštof, Vladimír (UEB-Q) RID, ORCID
Uldrijan, S. (CZ)Celkový počet autorů 2 Zdroj.dok. Current Drug Targets. - : Bentham Science Publishers - ISSN 1389-4501
Roč. 11, č. 3 (2010), s. 291-302Poč.str. 12 s. Jazyk dok. eng - angličtina Země vyd. NL - Nizozemsko Klíč. slova CDK ; protein kinase ; inhibitor Vědní obor RIV CE - Biochemie CEP GA204/08/0511 GA ČR - Grantová agentura ČR GA301/08/1649 GA ČR - Grantová agentura ČR LC06077 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy CEZ AV0Z50380511 - UEB-Q (2005-2011) UT WOS 000274419800004 Anotace Poor therapeutic outcomes and serious side effects, together with acquired resistance to multiple drugs, are common problems of current cancer therapies. Therefore, there is an urgent need for new cancer-targeted drugs, which has led (inter alia) to the development of molecules that can specifically inhibit cyclin-dependent kinases (CDKs). In addition to their cell cycle regulatory functions, CDKs, especially CDK7 and CDK9, play important roles in the regulation of RNA polymerase II-mediated transcription. Here, we report on progress in the preclinical development of CDK inhibitors and their anticancer activities. Special attention is paid to the action mechanisms of the pan-specific CDK inhibitors flavopiridol and roscovitine, which have already entered phase II clinical trials as treatments for various tumours. Pracoviště Ústav experimentální botaniky Kontakt David Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469 Rok sběru 2011
Počet záznamů: 1